Chairs
- Sara A. Hurvitz (Santa Monica, CA, United States of America)
- Miguel Martin (Madrid, Spain)
Welcome and introductions (ID 498)
Lecture Time
11:30 - 12:30
Speakers
- All Speakers (na, Switzerland)
Authors
- All Speakers (na, Switzerland)
Assessing risk of recurrence in HR-positive, HER2-negative early breast cancer (ID 499)
Lecture Time
12:30 - 12:30
Speakers
- All Speakers (na, Switzerland)
Authors
- All Speakers (na, Switzerland)
Impact of oral targeted adjuvant therapies in patients with HR-positive, HER2-negative early breast cancer (ID 500)
Lecture Time
12:30 - 12:30
Speakers
- All Speakers (na, Switzerland)
Authors
- All Speakers (na, Switzerland)
Optimizing adherence and persistence with oral targeted adjuvant therapies in HR-positive, HER2-negative early breast cancer (ID 501)
Lecture Time
12:30 - 12:30
Speakers
- All Speakers (na, Switzerland)
Authors
- All Speakers (na, Switzerland)
Shared decision-making in HR-positive, HER2-negative early breast cancer: Enhancing patient-provider communication (ID 502)
Lecture Time
12:30 - 12:30
Speakers
- All Speakers (na, Switzerland)
Authors
- All Speakers (na, Switzerland)
Questions and take-home messages (ID 503)
Lecture Time
12:30 - 12:30
Speakers
- All Speakers (na, Switzerland)
Authors
- All Speakers (na, Switzerland)